Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.33 |
| ▸ | CDK4 | P11802 | 5/20 | 0.33 |
| ▸ | CCND1 | P24385 | 5/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999859 | 0.74 | KMT2A (0.50) | KDM4EHSD17B10ALDH1A1CDK4CCND1 | |
| SCHEMBL7005388 | 0.72 | HPGD (0.55) | KDM4EHSD17B10ALDH1A1CDK4CCND1 | |
| SCHEMBL7004582 | 0.71 | HPGD (0.50) | KDM4EHSD17B10ALDH1A1LIPGCDK4 | |
| Hydrochloric Acid SCHEMBL7001168 | 0.69 | HTR2C (0.52) | KDM4EHSD17B10LIPGCDK4CCND1 | |
| SCHEMBL30915985 | 0.64 | MAOA (0.48) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL7005451 | 0.64 | HTR3A (0.36) | KDM4EHSD17B10ALDH1A1CDK4CCND1 | |
| SCHEMBL9650536 | 0.63 | CYP2B6 (0.46) | KDM4EALDH1A1LMNATSHR | |
| SCHEMBL8137309 | 0.62 | MCL1 (0.50) | LIPGLMNAMAPT | |
| Hydrochloric Acid SCHEMBL7001069 | 0.62 | HTR1A (0.71) | — | |
| SCHEMBL7005533 | 0.62 | MAPK1 (0.45) | HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | KDM4E 2332/4885HSD17B10 826/4885ALDH1A1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.